These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 9989126)

  • 1. Near-fatal skin picking from delusional body dysmorphic disorder responsive to fluvoxamine.
    O'Sullivan RL; Phillips KA; Keuthen NJ; Wilhelm S
    Psychosomatics; 1999; 40(1):79-81. PubMed ID: 9989126
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluvoxamine treatment of body dysmorphic disorder.
    Hollander E; Cohen L; Simeon D; Rosen J; DeCaria C; Stein DJ
    J Clin Psychopharmacol; 1994 Feb; 14(1):75-7. PubMed ID: 8151008
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of fluvoxamine in body dysmorphic disorder.
    Phillips KA; Dwight MM; McElroy SL
    J Clin Psychiatry; 1998 Apr; 59(4):165-71. PubMed ID: 9590666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delusionality and response to open-label fluvoxamine in body dysmorphic disorder.
    Phillips KA; McElroy SL; Dwight MM; Eisen JL; Rasmussen SA
    J Clin Psychiatry; 2001 Feb; 62(2):87-91. PubMed ID: 11247107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging skin-picking behaviour after serotonin reuptake inhibitor-treatment in patients with obsessive-compulsive disorder: possible mechanisms and implications for clinical care.
    Denys D; van Megen HJ; Westenberg HG
    J Psychopharmacol; 2003 Mar; 17(1):127-9. PubMed ID: 12680750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label escitalopram treatment for pathological skin picking.
    Keuthen NJ; Jameson M; Loh R; Deckersbach T; Wilhelm S; Dougherty DD
    Int Clin Psychopharmacol; 2007 Sep; 22(5):268-74. PubMed ID: 17690595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compulsive picking and obsessive-compulsive disorder.
    Stein DJ; Hutt CS; Spitz JL; Hollander E
    Psychosomatics; 1993; 34(2):177-81. PubMed ID: 8456163
    [No Abstract]   [Full Text] [Related]  

  • 8. Insight in obsessive compulsive disorder and body dysmorphic disorder.
    Eisen JL; Phillips KA; Coles ME; Rasmussen SA
    Compr Psychiatry; 2004; 45(1):10-5. PubMed ID: 14671731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder.
    Dell'Osso B; Allen A; Hollander E
    Expert Opin Pharmacother; 2005 Dec; 6(15):2727-40. PubMed ID: 16316311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The first Japanese pediatric case of obsessive-compulsive disorder who responded to a selective serotonin re-uptake inhibitor.
    Furusho J; Kubagawa T; Saitoh N; Matsuzaki K; Yamakawa H; Iikura Y
    Pediatr Int; 2000 Aug; 42(4):451-2. PubMed ID: 10986886
    [No Abstract]   [Full Text] [Related]  

  • 11. Late onset OCD.
    Bhattacharyya S; Khanna S
    Aust N Z J Psychiatry; 2004 Jun; 38(6):477-8. PubMed ID: 15209842
    [No Abstract]   [Full Text] [Related]  

  • 12. Resolution of Pathological Skin Picking With Fluvoxamine in a 74-Year-Old Dementia Patient.
    Hafeez ZH
    Prim Care Companion CNS Disord; 2016; 18(1):. PubMed ID: 27247839
    [No Abstract]   [Full Text] [Related]  

  • 13. Fluvoxamine in the treatment of corticosteroid-induced obsessive-compulsive disorder.
    Oulis P; Masdrakis VG; Florakis A; Papadimitriou GN
    Clin Neuropharmacol; 2009; 32(3):176-7. PubMed ID: 19483493
    [No Abstract]   [Full Text] [Related]  

  • 14. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study.
    Zanardi R; Franchini L; Serretti A; Perez J; Smeraldi E
    J Clin Psychiatry; 2000 Jan; 61(1):26-9. PubMed ID: 10695642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dysmorphophobia (body dysmorphic disorder)].
    Filteau MJ; Pourcher E; Baruch P; Bouchard RH; Vincent P
    Can J Psychiatry; 1992 Sep; 37(7):503-9. PubMed ID: 1423148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to fluvoxamine augmentation for obsessive and compulsive symptoms in schizophrenia.
    Dwivedi S; Pavuluri M; Heidenreich J; Wright T
    J Child Adolesc Psychopharmacol; 2002; 12(1):69-70. PubMed ID: 12014598
    [No Abstract]   [Full Text] [Related]  

  • 17. Outcome of additional behaviour therapy including treatment discontinuation for fluvoxamine non-responders with obsessive-compulsive disorder.
    Nakatani E; Nakagawa A
    Psychother Psychosom; 2008; 77(6):393-4. PubMed ID: 18716426
    [No Abstract]   [Full Text] [Related]  

  • 18. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Lafleur DL; Pittenger C; Kelmendi B; Gardner T; Wasylink S; Malison RT; Sanacora G; Krystal JH; Coric V
    Psychopharmacology (Berl); 2006 Jan; 184(2):254-6. PubMed ID: 16374600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions.
    Goodman WK; Ward H; Kablinger A; Murphy T
    J Clin Psychiatry; 1997; 58 Suppl 5():32-49. PubMed ID: 9184625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insight, overvalued ideation, and delusional thinking in body dysmorphic disorder: theoretical and treatment implications.
    Phillips KA; McElroy SL
    J Nerv Ment Dis; 1993 Nov; 181(11):699-702. PubMed ID: 8228952
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.